Systemic Lupus Erythematosus

Systemic Lupus Erythematosus — Internal Medicine

How it begins

Referencia ultra-detallada sobre la enfermedad autoinmune sistémica prototípica: epidemiología, inmunopatogénesis, criterios ACR/EULAR 2019, afectación multiorgánica, estrategias terapéuticas y manejo en situaciones especiales.

What it covers

1. Epidemiology, Genetics and Risk Factors
2. · Epidemiology
3. · Genetic Factors
4. · Triggering and Environmental Factors
5. Pathogenesis and Immunology
6. · The «Interferon Signature»: Central Axis of the LES
7. · Mechanisms of Tissue Damage Mediated by Autoantibodies
8. Diagnostic Criteria and Classification
9. · ACR/EULAR Criteria 2019
10. · SLICC 2012 Criteria: Complementary Value
11. Mucocutaneous Manifestations
12. · Specific Skin Lesions of Lupus
13. · Non-Specific Skin Manifestations
14. Aparato Locomotor
15. · Lupus Arthritis: Differential Characteristics
16. · Muscular Manifestations
17. Lupus Nephritis
18. · ISN/RPS Classification 2018 — Classes of Lupus Nephritis
19. · Indications for Renal Biopsy in SLE
20. · Treatment of Active Lupus Nephritis (Classes III/IV ± V)
21. Neuropsychiatric SLE (NPSLE)
22. · Pathogenic Mechanisms of NPSLE
23. · CNS manifestations in NPSLE
24. · SNP demonstrations in NPSLE
25. Cardiovascular and Pulmonary Manifestations
26. · Cardiovascular Manifestations
27. · Pulmonary Manifestations
28. Hematological Manifestations
29. · Anemia in SLE
30. · Leukopenia and Lymphopenia
31. · Thrombocytopenia
32. · Macrophage Activation Syndrome (MAS) in SLE
33. Antiphospholipid syndrome (APS)
34. · Sydney 2006 Classification Criteria (Revised)
35. · Pathogenesis of APS
36. · Clinical Manifestations of SAF
37. · Catastrophic SAF (CAPS)
38. Other Systemic Manifestations
39. · Gastrointestinal Manifestations
40. · Ecular Manifestations
41. · Constitutional Demonstrations
42. Laboratory and Autoantibodies
43. · Antibodies in SLE: Complete Table
44. · Complement as an Activity Marker
45. · Other Biochemical Parameters
46. Activity and Damage Rates
47. · Validated Activity Indices
48. Principles and Basal Treatment
49. · Hydroxychloroquine (HCQ): The Fundamental Pillar
50. · Photoprotection and General Measures
51. · Corticosteroids: Use them with Strategy
52. · Maintenance Immunosuppressants
53. Biological Therapies and New Targets
54. · Belimumab (anti-BLyS/BAFF) — The First Biologic Approved for SLE
55. · Anifrolumab (anti-IFN receptor type I) — The Second Biological for SLE
56. · Voclosporin in Lupus Nephritis
57. · Rituximab in SLE (Off-label Use)
58. · Emerging Therapies and Pipeline
59. Pregnancy and SLE
60. · Pregnancy Planning in SLE
61. · Safe Drugs vs. Contraindicated in Pregnancy
62. · Maternal and Fetal Complications
63. Comorbidities, Prognosis and Mortality
64. · Mortality in SLE: The Bimodal Pattern
65. · Poor Prognostic Factors in SLE
66. · Prevalent Comorbidities and Their Management